These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 30228778)

  • 61. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transforming Albumin into a Trojan Horse of Immunotherapy-Resistant Colorectal Cancer with a High Microsatellite Instability.
    Yang W; Li Z; Li Y; He W; Yan J
    ACS Nano; 2024 Jul; 18(29):19332-19344. PubMed ID: 38990329
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nutraceuticals in colorectal cancer: A mechanistic approach.
    Rossi M; Mirbagheri SEYEDS; Keshavarzian A; Bishehsari F
    Eur J Pharmacol; 2018 Aug; 833():396-402. PubMed ID: 29935172
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8
    Sun Z; Ren Z; Yang K; Liu Z; Cao S; Deng S; Xu L; Liang Y; Guo J; Bian Y; Xu H; Shi J; Wang F; Fu YX; Peng H
    Nat Commun; 2019 Aug; 10(1):3874. PubMed ID: 31462678
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
    Park R; Saeed A
    NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
    Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
    Front Immunol; 2018; 9():3107. PubMed ID: 30692993
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi M; Bartholin L; Neuzillet C
    World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer.
    Gurjao C; Liu D; Hofree M; AlDubayan SH; Wakiro I; Su MJ; Felt K; Gjini E; Brais LK; Rotem A; Rosenthal MH; Rozenblatt-Rosen O; Rodig S; Ng K; Van Allen EM; Corsello SM; Ogino S; Regev A; Nowak JA; Giannakis M
    Cancer Immunol Res; 2019 Aug; 7(8):1230-1236. PubMed ID: 31217164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
    Liu N; Shan F; Ma M
    Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
    [TBL] [Abstract][Full Text] [Related]  

  • 77. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.